Pellegrini Lucienne, Parrilli Gianpaolo, Santonicola Antonella, Cinquanta Luigi, Caputo Cesare, Ciacci Carolina, Zingone Fabiana
AOU San Giovanni di Dio e Ruggi d'Aragona, Liver Following Transplantation Centre, Department of Medicine and Surgery, University of Salerno, Salerno, Italy.
AOU San Giovanni di Dio e Ruggi d'Aragona, UOC Clinical Pathology Department, Salerno, Italy.
Biomed Res Int. 2017;2017:2456916. doi: 10.1155/2017/2456916. Epub 2017 Feb 27.
The relevance of isolated autoimmunity elevation in orthotopic liver transplantation (OLT) patients is unknown. Our aim was to analyse how serum autoantibodies change in time and to evaluate their clinical relevance in OLT patients. Patients were invited to provide samples to evaluate ANA, AMA, ASMA, and LKM at the time of enrolment (0), after 6 months (6), and after 12 months (12). We included 114 patients in the study (76% males, median age 62.5 years), finding isolated elevation of at least one serum antibody in up to 80% of them. We described fluctuating positive autoantibodies in the one year of observation, with only 45.6% of patients positive for ANA and less than 2% positive for ASMA, at all three times. Isolated elevation of tissue antibodies was not related to gender, age, HCC at transplant, early rejection, cause of transplantation, immunotherapy taken, and age at the time of the study. We did not detect a higher prevalence of positive autoimmunity in patients with signs of liver injury. ANA and ASMA evaluation in patients with liver transplantation and no history of autoimmune disease has no clinical relevance, since it varies in time and is not related to any risk factors or liver injury. Routine autoimmunity evaluation should be avoided.
原位肝移植(OLT)患者孤立性自身免疫升高的相关性尚不清楚。我们的目的是分析血清自身抗体如何随时间变化,并评估其在OLT患者中的临床相关性。在入组时(0个月)、6个月后(6个月)和12个月后(12个月)邀请患者提供样本,以评估抗核抗体(ANA)、抗线粒体抗体(AMA)、抗平滑肌抗体(ASMA)和抗肝肾微粒体抗体(LKM)。我们纳入了114例患者进行研究(76%为男性,中位年龄62.5岁),发现其中高达80%的患者至少有一种血清抗体孤立性升高。我们描述了在一年的观察期内自身抗体呈波动阳性,在所有三个时间点,ANA阳性的患者仅为45.6%,ASMA阳性的患者不到2%。组织抗体的孤立性升高与性别、年龄、移植时的肝细胞癌、早期排斥反应、移植原因、所接受的免疫治疗以及研究时的年龄无关。我们没有在有肝损伤迹象的患者中检测到更高的自身免疫阳性率。对无自身免疫性疾病病史的肝移植患者进行ANA和ASMA评估没有临床意义,因为其随时间变化,且与任何风险因素或肝损伤均无关。应避免进行常规自身免疫评估。